Burma Blue Lotus (Nymphaea caerulea)

Burma Blue Lotus (Nymphaea caerulea) is an aquatic plant historically used in ancient Egyptian and Ayurvedic traditions, containing alkaloids nuciferine and aporphine as its primary bioactive compounds. Nuciferine acts as a dopamine receptor antagonist and serotonin receptor modulator, which may underlie reported mild sedative and mood-altering effects.

Origin & History

Burma Blue Lotus (Nymphaea caerulea) is a cultivar variant of the blue water lily native to the Nile region of Egypt and East Africa, cultivated in regions like Burma (Myanmar) for its striking blue flowers. Extracts are typically obtained via ethanol or methanol extraction from flowers, yielding concretes or absolutes containing complex mixtures of compounds rather than isolated alkaloids.

Historical & Cultural Context

Nymphaea caerulea has been used in ancient Egyptian traditional medicine since approximately 2000 BCE as an intoxicant, aphrodisiac, and in religious rituals as depicted in temple art. It was traditionally consumed as wine infusions or smoked for euphoric and sedative effects in Nile Valley cultures.

Health Benefits

• Potential antioxidant activity from flavonoids and phenols (in vitro evidence only)
• Traditional use as aphrodisiac attributed to apomorphine content (though virtually absent in authentic extracts)
• Possible sedative and euphoric effects from traditional preparations (no clinical evidence)
• In vitro anti-inflammatory potential from alkaloids like lotusine and neferine (preliminary evidence)
• Traditional use for relaxation and mood enhancement (historical use only, no clinical trials)

How It Works

Nuciferine, the primary alkaloid in Nymphaea caerulea, acts as an antagonist at dopamine D2 and D4 receptors and as a partial agonist or modulator at serotonin 5-HT2A and 5-HT2C receptors, which may produce mild euphoric and sedative effects. The flavonoid miquelianin (quercetin-3-O-glucuronide) inhibits pro-inflammatory enzymes COX-1 and COX-2 and scavenges reactive oxygen species via electron donation, contributing to in vitro antioxidant activity. Contrary to popular belief, authentic commercial extracts contain negligible apomorphine — a dopamine agonist frequently cited as the source of aphrodisiac effects — making that specific mechanism clinically irrelevant for most commercial products.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Nymphaea caerulea or its Burma Blue Lotus cultivar variant. PubMed searches yielded no relevant PMIDs for clinical studies, with research focusing primarily on chemical composition analysis via GC-MS and in vitro properties.

Clinical Summary

No randomized controlled trials or formal human clinical studies have been conducted specifically on Nymphaea caerulea extracts for any health indication as of 2024. Available evidence is limited to in vitro cell studies demonstrating antioxidant activity from flavonoid fractions, isolated animal studies showing nuciferine-induced sedation in rodent models, and ethnobotanical and historical reports from ancient Egyptian and Southeast Asian traditions. A small number of case reports and pharmacological analyses have identified psychoactive effects — including mild sedation and altered perception — in individuals consuming high-dose preparations or blue lotus wine, but these lack controlled methodology. The overall evidence base is preclinical and anecdotal, and no therapeutic claims can be substantiated for human health outcomes.

Nutritional Profile

Burma Blue Lotus (Nymphaea caerulea) is not consumed as a significant source of macronutrients or conventional micronutrients; its profile is dominated by bioactive phytochemicals. Macronutrient content is negligible in typical use forms (dried flowers, extracts, teas). Key bioactive compounds include: alkaloids — nuciferine (estimated 0.1–0.5% dry weight in petals, the primary psychoactive constituent acting as a dopamine receptor modulator), apomorphine (present at trace or virtually undetectable levels, <0.001% in authenticated commercial material, often cited but analytically disputed), lotusine, liensinine, and neferine (combined alkaloid fraction approximately 0.05–0.2% dry weight). Flavonoids — myricetin, quercetin, kaempferol, and isorhamnetin are present, with total flavonoid content estimated at 1–3% dry weight in flower petals; these contribute to reported antioxidant activity (DPPH scavenging IC50 values reported in vitro at 50–150 µg/mL depending on extract). Phenolic acids — gallic acid and ellagic acid derivatives present at approximately 0.5–1.5% dry weight total phenolics. Glycosides — including nymphayol and sitosterol glycosides at trace levels. Minerals: limited data; minor amounts of potassium, calcium, and magnesium typical of aquatic plant material but not nutritionally significant at consumed doses. Bioavailability: alkaloids including nuciferine show reasonable oral bioavailability in animal models, with CNS penetration demonstrated; flavonoid bioavailability is moderate and enhanced by lipid co-consumption; apomorphine, even if present at trace levels, undergoes significant first-pass metabolism, limiting systemic exposure markedly.

Preparation & Dosage

No clinically studied dosage ranges are available as no human clinical trials exist. Commercial products show highly variable alkaloid content, and authentic extracts lack significant apomorphine and nuciferine, precluding standardization recommendations. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ashwagandha, L-Theanine, Passionflower, Rhodiola, Chamomile

Safety & Interactions

Burma Blue Lotus is generally considered low-risk at typical supplemental doses, but high doses of nuciferine may potentiate CNS depressants including benzodiazepines, alcohol, and opioids due to its serotonin and dopamine receptor activity, increasing sedation risk. Because nuciferine antagonizes dopamine D2 receptors, concurrent use with dopaminergic medications such as levodopa or antipsychotics could produce unpredictable pharmacodynamic interactions. Nymphaea caerulea is not recommended during pregnancy or breastfeeding due to the complete absence of safety data and theoretical uterine stimulant effects suggested in traditional use contexts. The plant is classified as a controlled or monitored substance in some jurisdictions including Poland and Russia, and consumers should verify legal status in their region before purchase.